Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

NCT03556839 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Cáncer de Ovario as lead sponsor.

NCT NCT03556839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03556839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Lead sponsor
Grupo Español de Investigación en Cáncer de Ovario
Phase
Phase 3
Overall status
Completed
Start date
September 25, 2018
Completion date
August 31, 2025
Enrollment
410 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma of the cervix, stage ivb